Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $2.8 million.

  • Ernexa Therapeutics' Non-Current Assets fell 652.61% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 9119.59%. This contributed to the annual value of $2.9 million for FY2024, which is 9262.14% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Non-Current Assets of $2.8 million as of Q3 2025, which was down 652.61% from $2.8 million recorded in Q2 2025.
  • Ernexa Therapeutics' Non-Current Assets' 5-year high stood at $45.2 million during Q3 2023, with a 5-year trough of $2.8 million in Q2 2025.
  • For the 5-year period, Ernexa Therapeutics' Non-Current Assets averaged around $16.9 million, with its median value being $9.4 million (2022).
  • Per our database at Business Quant, Ernexa Therapeutics' Non-Current Assets soared by 79115.1% in 2023 and then tumbled by 9349.23% in 2025.
  • Ernexa Therapeutics' Non-Current Assets (Quarter) stood at $13.6 million in 2021, then plummeted by 36.95% to $8.6 million in 2022, then surged by 359.79% to $39.5 million in 2023, then crashed by 92.62% to $2.9 million in 2024, then dropped by 4.25% to $2.8 million in 2025.
  • Its Non-Current Assets was $2.8 million in Q3 2025, compared to $2.8 million in Q2 2025 and $2.8 million in Q1 2025.